Status:
RECRUITING
Targeted Optical Biopsy for Local Rectal Scars in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Rectal Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Currently, low concordance (36%) is found between clinical complete response and pathologic complete response in patients with rectal cancer after neoadjuvant chemoradiotherapy. Probe-based confocal l...
Detailed Description
Patients with locally advanced rectal cancer can benefit from neoadjuvant chemoradiotherapy, and 20%-30% of patients receiving such therapy can attain a pathologic complete response, defined as the er...
Eligibility Criteria
Inclusion
- Age from over 18 to under 80 years
- American Society of Anesthesiology(ASA) score class I,II,or III
- Locally advanced rectal cancer
- Patient has completed standard neoadjuvant therapy
- Expected surgical resection
- Written informed consent
Exclusion
- Pregnant or lactating women
- Acute renal insufficiency or stage II to IV chronic renal insufficiency
- Patients with allergic constitution
Key Trial Info
Start Date :
November 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT05316103
Start Date
November 4 2021
End Date
November 1 2026
Last Update
May 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510000